Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.41%
#4 aPriori aPriori +160.22%
#5 Bedrock Bedrock +74.34%
#6 Cysic Cysic +50.91%
#7 Prom Prom +46.77%
#8 Playnance Playnance +34.90%
#9 Bitway Bitway +28.95%
#10 COTI COTI +25.85%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Alseres Pharmaceuticals, Inc. Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc.

ALSE
Rank in Stocks #42806
Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and... Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and therapeutic solutions, with a primary emphasis on ailments affecting the central nervous system. Their flagship experimental compound is Altropane, a molecular imaging agent developed for identifying and diagnosing Parkinson's disease and dementia. Founded in 1972, the company was previously known as Boston Life Sciences, Inc. before officially changing its name to Alseres Pharmaceuticals, Inc. in June 2007. Its operations are headquartered in Auburndale, Massachusetts.
Share Price
$0.01
Last synced: 2024-08-19
Market Cap
$61.27
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alseres Pharmaceuticals, Inc. (ALSE)

Category

Healthcare
P/E ratio for Alseres Pharmaceuticals, Inc. (ALSE)
P/E ratio as of 2026 TTM: 0
According to Alseres Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Alseres Pharmaceuticals, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.